Publication:
ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure.

cris.virtual.author-orcid0000-0001-7896-6188
cris.virtualsource.author-orcid37adcc41-bab0-4cfb-bc5f-05fb501fab99
datacite.rightsopen.access
dc.contributor.authorOczkowski, Simon
dc.contributor.authorErgan, Begüm
dc.contributor.authorBos, Lieuwe
dc.contributor.authorChatwin, Michelle
dc.contributor.authorFerrer, Miguel
dc.contributor.authorGregoretti, Cesare
dc.contributor.authorHeunks, Leo
dc.contributor.authorFrat, Jean-Pierre
dc.contributor.authorLonghini, Federico
dc.contributor.authorNava, Stefano
dc.contributor.authorNavalesi, Paolo
dc.contributor.authorUğurlu, Aylin Ozsancak
dc.contributor.authorPisani, Lara
dc.contributor.authorRenda, Teresa
dc.contributor.authorThille, Arnaud W
dc.contributor.authorWinck, João Carlos
dc.contributor.authorWindisch, Wolfram
dc.contributor.authorTonia, Thomai
dc.contributor.authorBoyd, Jeanette
dc.contributor.authorSotgiu, Giovanni
dc.contributor.authorScala, Raffaele
dc.date.accessioned2024-10-05T06:51:40Z
dc.date.available2024-10-05T06:51:40Z
dc.date.issued2022-04
dc.description.abstractBACKGROUND High-flow nasal cannula (HFNC) has become a frequently used non-invasive form of respiratory support in acute settings, however evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF). MATERIALS AND METHODOLOGY The European Respiratory Society Task Force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The Task Force used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and non-invasive ventilation (NIV) for the management of adults in acute settings with ARF. RESULTS The Task Force developed 8 conditional recommendations, suggesting using: 1) HFNC over COT in hypoxemic ARF, 2) HFNC over NIV in hypoxemic ARF, 3)HFNC over COT during breaks from NIV, 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications, 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications, 6) HFNC over COT in non-surgical patients at low risk of extubation failure, 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV, 8) trialling NIV prior to use of HFNC in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic ARF. CONCLUSIONS HFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of non-invasive respiratory support to provide to patients in different acute settings.
dc.description.noteSimon Oczkowski and Begüm Ergan act as co-first authors Task force report
dc.description.numberOfPages105
dc.description.sponsorshipInstitut für Sozial- und Präventivmedizin (ISPM)
dc.identifier.doi10.48350/160267
dc.identifier.pmid34649974
dc.identifier.publisherDOI10.1183/13993003.01574-2021
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/53793
dc.language.isoen
dc.publisherEuropean Respiratory Society
dc.relation.ispartofEuropean respiratory journal
dc.relation.issn0903-1936
dc.relation.organizationDCD5A442BECFE17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.titleERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
dspace.file.typetext
oaire.citation.issue4
oaire.citation.startPage2101574
oaire.citation.volume59
oairecerif.author.affiliationInstitut für Sozial- und Präventivmedizin (ISPM)
oairecerif.identifier.urlhttps://erj.ersjournals.com/lens/erj/early/2021/09/29/13993003.01574-2021
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.embargoChanged2023-04-15 22:25:02
unibe.date.licenseChanged2022-04-29 07:37:44
unibe.description.ispublishedpub
unibe.eprints.legacyId160267
unibe.journal.abbrevTitleEUR RESPIR J
unibe.refereedtrue
unibe.subtype.articlereview

Files

Original bundle
Now showing 1 - 2 of 2
Name:
Oczkowski_EurRespirJ_2021_AAM.pdf
Size:
6.84 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
accepted
Name:
Oczkowski_EurRespirJ_2022.pdf
Size:
672.3 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections